---
title: "The innovative drug concept continues to strengthen, Hotgen rises over 15%, reaching a historic high"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/247229059.md"
description: "The innovative drug concept has repeatedly strengthened, with Hotgen rising over 15%, continuing to set new historical highs. Previously, Saili Medical had four consecutive trading limits, Zhongyuan Union hit the limit, and Shenzhou Cell, Guangsheng Tang, Shanghai Yizhong, and Rongchang Bio saw significant gains"
datetime: "2025-07-04T01:39:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/247229059.md)
  - [en](https://longbridge.com/en/news/247229059.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/247229059.md)
generator: "portal-rs"
---

# The innovative drug concept continues to strengthen, Hotgen rises over 15%, reaching a historic high

The innovative drug concept has repeatedly strengthened, with Hotgen rising over 15%, continuing to set new historical highs. Previously, Saili Medical had four consecutive trading limits, Zhongyuan Union reached the trading limit, and Shenzhou Cell, Guangsheng Tang, Shanghai Yizhong, and Rongchang Bio also saw significant gains

### Related Stocks

- [688068.CN](https://longbridge.com/en/quote/688068.CN.md)

## Related News & Research

- [Turning Point USA announces Charlie Kirk memorial on university campus where he was shot](https://longbridge.com/en/news/296708182.md)
- [11:00 ETCizzle Bio Highlights CIZ1B Biomarker Blood Test for Lung Cancer at Next Generation Dx Summit](https://longbridge.com/en/news/297064751.md)
- [Bioretec hosts media event highlighting 500,000 Activa bioresorbable orthopedic implants sold worldwide](https://longbridge.com/en/news/297047388.md)
- [14:02 ETProject Lifesaver Partners With FaceTec to Identify At-Risk Children and Adults](https://longbridge.com/en/news/297076808.md)
- [SalMar – Record-strong biological performance](https://longbridge.com/en/news/296859687.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**